Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 128 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Fetal Alcohol Syndrome, Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder (ADD)
Interventions
Strattera, Placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
4 Years to 11 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Atomoxetine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Completed Phase 1Phase 2 Interventional Results available

Atomoxetine and Oxybutynin in Obstructive Sleep Apnea

NCT02908529
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
Combination product of Atomoxetine and Oxybutynin, Placebo, 2 tablets
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Results available

Cognitive Decline in Non-demented PD

NCT01340885
Conditions
Parkinson's Disease
Interventions
Strattera, Exelon, Placebo
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Schizophrenia
Interventions
olanzapine, atomoxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
20
States / cities
Cerritos, California • Chula Vista, California • Garden Grove, California + 15 more
Conditions
Attention Deficit Hyperactivity Disorder, Substance Use Disorder
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
15 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Methamphetamine Abuse, Methamphetamine Dependence
Interventions
Atomoxetine, then Placebo, Placebo, then Atomoxetine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Cancer, Cognitive Late Effects
Interventions
Atomoxetine
Drug
Lead sponsor
Temple University
Other
Eligibility
6 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Sugar Pill
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
7 Years to 12 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Atomoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 16 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
21
States / cities
Pasadena, California • Rolling Hills Estates, California • Spring Valley, California + 18 more
Conditions
Cannabis Dependence
Interventions
Atomoxetine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
20
States / cities
Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
Conditions
Autism, Pervasive Development Disorder, Asperger's Disorder, Attention Deficit Hyperactivity Disorder
Interventions
atomoxetine, Placebo, Parent Management Training
Drug · Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
5 Years to 14 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Rochester, New York • Columbus, Ohio • Pittsburgh, Pennsylvania
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO), Guanfacine (GFC)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
17,418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Titusville, New Jersey
Conditions
Depressive Symptoms
Interventions
Atomoxetine Hydrochloride, Sertraline, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Fetal Alcohol Syndrome, Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Atomoxetine
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
4 Years to 11 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Menopause, Cognitive Disturbances
Interventions
atomoxetine, placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Substance Use Disorders, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
13 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Traumatic Brain INjury
Interventions
atomoxetine, placebo
Drug
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Englewood, Colorado
Conditions
OSA - Obstructive Sleep Apnea
Interventions
AD109, AD504, Atomoxetine Hydrochloride, Placebo
Drug
Lead sponsor
Apnimed
Industry
Eligibility
18 Years to 75 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
25
States / cities
Los Angeles, California • San Diego, California • Santa Ana, California + 21 more
Completed Phase 2 Interventional Results available

Crossover Trial of AD036 in Obstructive Sleep Apnea

NCT04445688
Conditions
Obstructive Sleep Apnea
Interventions
AD036, Atomoxetine, Placebo
Drug
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Little Rock, Arkansas • Santa Ana, California • Chevy Chase, Maryland + 2 more
Conditions
Obstructive Sleep Apnea, Hypertension
Interventions
AD113, Atomoxetine
Drug
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Towson, Maryland • Cincinnati, Ohio • Columbia, South Carolina
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
Positive airway pressure (PAP) therapy, Sleep dental device, Atomoxetine-oxybutynin
Device · Drug
Lead sponsor
Sairam Parthasarathy
Other
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Tucson, Arizona • Redwood City, California • Miami, Florida + 1 more